Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Michail Shadkin who wrote (2788)	6/24/2001 6:06:03 PM
From: tuck	Respond to of 6873

Michail, I was looking at shorting IPIC myself, until I bounced the idea off of a couple of bioscience types. My own initial digging confirms that their lead compound pagoclone has good chances in a large market: Message 15982702 and the posts before and after. While the royalties aren't huge -- in the 10% range in part because partner Pfizer is footing the clinical bills -- neither is the burn, as you noted. So the earnings (or cash flow, more precisely) are likely to be very sensitive to variations in revenue. What had held the stock down was the potential for a negative legal earnings impact large enough to overwhelm this. That's gone, and now the stock, despite its run and all the red flags and history, can still be seen as undervalued relative to many biotechs. Playing with fundamental fire here at these levels; risk/reward high both long and short, IMHO. Surer ones around, I think, but I encourage folks to follow the links and then some, and think for themselves. I have no position, and don't expect to try one soon, though I might consider going long should it retrace hard -- say to the 4s or worse -- without obvious justification. Cheers, Tuck